Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Lymphoma 6Small Cell Lung Carcinoma 5Breast Neoplasms 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Mantle-Cell 2Burkitt Lymphoma 2Advanced Solid Tumors 2Advanced Nonhematologic Malignancies 2Advanced Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Immunoblastic Lymphadenopathy 1Fallopian Tube Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

sapanisertib 2MLN 8237 2tovorafenib 1serabelisib 1pevonedistat 1TAK 733 1Paclitaxel 1Irinotecan 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Nonhematologic Malignancies × MLN 8237 × Clear all
NCT02327169 2020-02-25

A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies

Takeda

Phase 1 Completed
81 enrolled 33 charts

Advanced Nonhematologic Malignancies

NCT01613261 2013-11-01

Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.

Phase 1 Withdrawn

Advanced Nonhematologic Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡